LYFIX: AlphaCentric LifeSci Healthcare I

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

Channels

Fixed income news, reports, video and more.

Municipal bonds news, reports, video and more.

Practice management news, reports, video and more.

Portfolio management news, reports, video and more.

Retirement news, reports, video and more.

Learn from industry thought leaders and expert market participants.

Deepen your understanding of Responsible Investing and learn how it can potentially help you build a more successful practice.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

LYFIX AlphaCentric LifeSci Healthcare I


Profile

LYFIX - Profile

Vitals

  • YTD Return 23.3%
  • 3 Yr Annualized Return N/A
  • 5 Yr Annualized Return N/A
  • Net Assets $2.42 M
  • Holdings in Top 10 40.6%

52 WEEK LOW AND HIGH

$12.48
$8.39
$12.48

Expenses

OPERATING RELATED FEES

  • Expense Ratio 24.14%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 215.00%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $2,500
  • IRA $2,500

Fund Classification


Distributions

  • YTD Total Return 23.3%
  • 3 Yr Annualized Total Return N/A
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.23%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    AlphaCentric LifeSci Healthcare Fund
  • Fund Family Name
    AlphaCentric Funds
  • Inception Date
    Nov 29, 2019
  • Shares Outstanding
    N/A
  • Share Class
    Inst
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Mark Charest

Fund Description

The fund will invest at least 80% of its net assets plus borrowings for investment purposes in the securities of companies in the life sciences and healthcare sectors, which the advisor defines to be the category of companies related to producing or supplying facilities, supplies, technology, pharmaceuticals, equipment, devices or services for the preservation and care of a person's health. It will invest in the equity securities, primarily common stock, of these companies and may also invest, from time to time, in ETFs that primarily invest in these companies. It is non-diversified.


Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.


Categories

Performance

LYFIX - Performance

Return Ranking - Trailing

Period LYFIX Return Category Return Low Category Return High Rank in Category (%)
YTD 23.3% -9.8% 24.3% 3.10%
1 Yr N/A 1.4% 41.8% N/A
3 Yr N/A* -13.0% 19.5% N/A
5 Yr N/A* -11.2% 13.1% N/A
10 Yr N/A* -1.7% 17.0% N/A

* Annualized

Return Ranking - Calendar

Period LYFIX Return Category Return Low Category Return High Rank in Category (%)
2019 N/A 5.7% 55.4% N/A
2018 N/A -25.3% 21.5% N/A
2017 N/A -10.8% 43.9% N/A
2016 N/A -31.6% 6.9% N/A
2015 N/A -20.4% 13.8% N/A

Total Return Ranking - Trailing

Period LYFIX Return Category Return Low Category Return High Rank in Category (%)
YTD 23.3% -9.8% 24.3% 3.10%
1 Yr N/A 1.4% 41.8% N/A
3 Yr N/A* -13.0% 22.5% N/A
5 Yr N/A* -11.2% 17.9% N/A
10 Yr N/A* -1.7% 19.1% N/A

* Annualized

Total Return Ranking - Calendar

Period LYFIX Return Category Return Low Category Return High Rank in Category (%)
2019 N/A 5.7% 55.4% N/A
2018 N/A -25.3% 22.2% N/A
2017 N/A -10.8% 45.8% N/A
2016 N/A -26.4% 8.7% N/A
2015 N/A -16.6% 15.2% N/A

NAV & Total Return History


Holdings

LYFIX - Holdings

Concentration Analysis

LYFIX Category Low Category High LYFIX % Rank
Net Assets 2.42 M 2.42 M 49.6 B 100.00%
Number of Holdings 56 27 433 86.67%
Net Assets in Top 10 952 K 784 K 18.8 B 93.33%
Weighting of Top 10 40.55% 23.2% 75.9% 45.93%

Top 10 Holdings

  1. First American Government Obligs U 8.39%
  2. Fidelity® Inv MM Fds Government I 6.78%
  3. Athira Pharma, Inc. Private Stock 6.07%
  4. Alexion Pharmaceuticals Inc 3.46%
  5. Zogenix Inc 3.16%
  6. Exelixis Inc 3.13%
  7. Jazz Pharmaceuticals PLC 2.94%
  8. Collegium Pharmaceutical Inc 2.35%
  9. Merck & Co Inc 2.14%
  10. Gilead Sciences Inc 2.13%

Asset Allocation

Weighting Return Low Return High LYFIX % Rank
Stocks
61.47% 61.47% 100.23% 100.00%
Cash
32.46% -0.23% 32.46% 2.22%
Other
6.07% -3.74% 6.07% 2.22%
Preferred Stocks
0.00% 0.00% 6.63% 51.85%
Convertible Bonds
0.00% 0.00% 0.00% 41.48%
Bonds
0.00% 0.00% 16.11% 44.44%

Stock Sector Breakdown

Weighting Return Low Return High LYFIX % Rank
Healthcare
100.00% 61.81% 100.00% 14.81%
Utilities
0.00% 0.00% 0.00% 41.48%
Technology
0.00% 0.00% 20.28% 48.89%
Real Estate
0.00% 0.00% 6.03% 45.93%
Industrials
0.00% 0.00% 6.39% 43.70%
Financial Services
0.00% 0.00% 2.43% 65.93%
Energy
0.00% 0.00% 0.00% 41.48%
Communication Services
0.00% 0.00% 3.18% 44.44%
Consumer Defense
0.00% 0.00% 34.31% 47.41%
Consumer Cyclical
0.00% 0.00% 1.12% 47.41%
Basic Materials
0.00% 0.00% 2.61% 57.04%

Stock Geographic Breakdown

Weighting Return Low Return High LYFIX % Rank
US
47.91% 47.91% 99.43% 100.00%
Non US
13.56% 0.00% 43.93% 68.15%

Expenses

LYFIX - Expenses

Operational Fees

LYFIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 24.14% 0.10% 25.14% 2.27%
Management Fee 1.25% 0.00% 1.25% 97.78%
12b-1 Fee 0.00% 0.00% 1.00% 2.78%
Administrative Fee N/A 0.03% 0.40% N/A

Sales Fees

LYFIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

LYFIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

LYFIX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 215.00% 0.70% 248.00% 96.95%

Distributions

LYFIX - Distributions

Dividend Yield Analysis

LYFIX Category Low Category High LYFIX % Rank
Dividend Yield 0.00% 0.00% 0.05% 42.96%

Dividend Distribution Analysis

LYFIX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Net Income Ratio Analysis

LYFIX Category Low Category High LYFIX % Rank
Net Income Ratio -0.23% -2.53% 2.12% 57.89%

Capital Gain Distribution Analysis

LYFIX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

LYFIX - Fund Manager Analysis

Managers

Mark Charest


Start Date

Tenure

Tenure Rank

Nov 29, 2019

0.76

0.8%

Dr. Charest has served as a portfolio manager of LifeSci Fund Management since 2019. In 2017, he founded Phenomic Capital LLC to provide investment advice and consulting services focused on the healthcare sector. In 2019 Phenomic Capital became an affiliated majority owner of the LifeSci Fund Management. From 2015 to 2016, Mark was SVP at Tekla Capital Management, focused on public and private healthcare technology investments. Between 2012 and 2015, he was Portfolio Manager at New Leaf Venture Partners, focused on public healthcare technology investments. From 2010 to 2012, Dr. Charest was a Kauffman Fellow at Panorama Capital where he served on the board of directors of Itero Biopharmaceuticals and was a board observer at Presidio Pharmaceuticals and PowerVision. Dr. Charest is an inventor on eight drug patents. Prior to his investment career, he held an operating role in the oncology area as a Medicinal Chemistry Lab Manager at the Novartis Institutes for BioMedical Research. Dr. Charest earned his PhD in chemistry and chemical biology from Harvard University as a National Science Foundation Graduate Research Fellow, his MS in chemistry and chemical biology from Harvard University, and his BA in chemistry, with Highest Honors, from Rutgers University.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.01 22.98 8.69 20.35